NCT05525234 is a Phase 4 clinical trial of Thalidomide in Haemodialysis, sponsored by RenJi Hospital.

Who is sponsoring NCT05525234?

NCT05525234 is sponsored by RenJi Hospital.

What drugs are being tested in NCT05525234?

Interventions in NCT05525234: Thalidomide, Placebo.

What condition does NCT05525234 study?

NCT05525234 studies Haemodialysis, Uremic Pruritus, Thalidomide.

Is NCT05525234 still recruiting?

NCT05525234 is currently status unknown. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT05525234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

Status unknown Phase 4 Last updated 1 September 2022

What this trial tests

Phase 4 trial testing Thalidomide in Haemodialysis in 40 participants. Status unknown.

Timeline

15 September 2022

Primary endpoint
31 December 2022

31 January 2023

Quick facts

Lead sponsor	RenJi Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	15 September 2022
Primary completion	31 December 2022
Estimated completion	31 January 2023

Drugs / interventions tested

Thalidomide (THALIDOMIDE) — full drug profile →
Placebo

Conditions studied

Haemodialysis — all drugs for Haemodialysis →
Uremic Pruritus — all drugs for Uremic Pruritus →
Thalidomide — all drugs for Thalidomide →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Haemodialysis or Uremic Pruritus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Thalidomide

Trials testing the same drug.

NCT06772480 — Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG T · NA · not yet recruiting
NCT06617182 — Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. · Phase 2 · recruiting
NCT06382519 — Thalidomide Therapy for VEOIBD · recruiting
NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
NCT06299670 — Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of T · Phase 4 · unknown

Other recruiting trials for Haemodialysis

Currently open trials in the same condition.

NCT07427264 — The Effect of a Mixed-type Intradialytic Exercise Training Program on Body Composition, Functional Capacity, and Muscle · NA · active not recruiting
NCT06641765 — Continuous Glucose Monitoring in Dialysis Patients With Diabetes · NA · active not recruiting
NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
NCT04842591 — Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation · active not recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05525234 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing